**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Dimitrios Bampatsias, Columbia University Irving Medical Center, New York, NY, USA

**Main Body of the Abstract**
Background:Natriuretic peptides (NPs) are prognostic biomarkers in ATTR-CM. Patients in atrial fibrillation (AF) have higher levels on NPs compared to patients in sinus rhythm (SR), but AF is not independently associated with survival in ATTR-CM. Currently there is limited data about the interaction between NPs, AF, and survival in patients receiving tafamidis.
Methods: This is a retrospective study, including 193 patients (85% males) with ATTR-CM receiving tafamidis from 2016 to 2023. N-terminal pro-B natriuretic peptide (Nt-proBNP) was measured at time of diagnosis. We assessed the impact of AF on survival by Kaplan Meier curves and log-rank test, uni- and multivariable Cox regression. ROC curves were constructed to determine the optimal Nt-proBNP cut off for death prediction.
Results:  Median age was 77.00 (73.25-83.00) years with 76 patients being in SR and 118 in AF. Patients in AF presented significantly higher median levels of Nt-proBNP (2,484 vs 1,515 pg/mL, p<0.001).  In the total cohort, AF was not associated with worse survival (Figure A). After ROC curve analysis, Nt-proBNP>2500 pg/mL was predictive of death. Following subgroup analysis, in patients with Nt-proBNP >2500 pg/mL, those in AF presented worse survival (Figure B), but lost significance after Cox regression adjusted for age, genotype, glomerular filtration rate and Nt-proBNP levels. The presence of AF was not associated with worse survival in patients with Nt-proBNP <2500 pg/mL (Figure C).
Conclusion: Even though atrial fibrillation is associated with higher levels of NPs; its presence does not modify their prognostic significance in patients with ATTR-CM receiving tafamidis.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Dimitrios Bampatsias, Columbia University Irving Medical Center, New York, NY, USA

**Main Body of the Abstract**
**Background:**Natriuretic peptides (NPs) are prognostic biomarkers in ATTR-CM. Patients in atrial fibrillation (AF) have higher levels on NPs compared to patients in sinus rhythm (SR), but AF is not independently associated with survival in ATTR-CM. Currently there is limited data about the interaction between NPs, AF, and survival in patients receiving tafamidis.
**Methods:** This is a retrospective study, including 193 patients (85% males) with ATTR-CM receiving tafamidis from 2016 to 2023. N-terminal pro-B natriuretic peptide (Nt-proBNP) was measured at time of diagnosis. We assessed the impact of AF on survival by Kaplan Meier curves and log-rank test, uni- and multivariable Cox regression. ROC curves were constructed to determine the optimal Nt-proBNP cut off for death prediction.
**Results:**  Median age was 77.00 (73.25-83.00) years with 76 patients being in SR and 118 in AF. Patients in AF presented significantly higher median levels of Nt-proBNP (2,484 vs 1,515 pg/mL, p<0.001).  In the total cohort, AF was not associated with worse survival (Figure A). After ROC curve analysis, Nt-proBNP>2500 pg/mL was predictive of death. Following subgroup analysis, in patients with Nt-proBNP >2500 pg/mL, those in AF presented worse survival (Figure B), but lost significance after Cox regression adjusted for age, genotype, glomerular filtration rate and Nt-proBNP levels. The presence of AF was not associated with worse survival in patients with Nt-proBNP <2500 pg/mL (Figure C).
**Conclusion:** Even though atrial fibrillation is associated with higher levels of NPs; its presence does not modify their prognostic significance in patients with ATTR-CM receiving tafamidis.



Natriuretic peptides, atrial fibrillation, and survival in patients with transthyretin cardiomyopathy receiving tafamidis treatment. PC68 (#395)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.